Literature DB >> 1869751

Effect of intracoronary diltiazem on infarct size and regional myocardial function in the ischemic reperfused canine heart.

L Higginson1, A Tang, G Knoll, J Calvin.   

Abstract

This study was designed to investigate whether intracoronary diltiazem given before reperfusion could enhance myocardial salvage in the canine heart. Twenty-five dogs were subjected to 90 min of coronary occlusion followed by 4 h of reperfusion. The dogs were assigned to one of three experimental groups. The early diltiazem group received intracoronary diltiazem into the distal coronary bed at the onset of coronary occlusion and for 60 min after reperfusion. The late diltiazem group received the same amount of drug beginning 15 min before reperfusion and the control group received saline solution for 90 min of occlusion and 60 min of reperfusion. Infarct size expressed as a percent of the area at risk was significantly smaller in the early and late diltiazem groups (15.6 +/- 3.6% and 21.2 +/- 5.1%, respectively) than in the control group (49 +/- 4.6%) (p less than 0.05). Intracoronary diltiazem restored systolic function of the stunned, previously ischemic tissue to essentially normal preocclusion values. Segmental shortening after reperfusion averaged 21.6% in the early diltiazem group versus 0 +/- 1.7% and 7.3 +/- 4% for the control and late diltiazem groups, respectively (p less than 0.05). Low dose intracoronary diltiazem did not alter hemodynamic variables or myocardial blood flow but did improve segmental shortening 2 and 6 h after reperfusion. These data indicate that intracoronary diltiazem given during occlusion or just before reperfusion increases the salvage of myocardium compared with the salvage achieved by reperfusion alone. These results also suggest that intracoronary diltiazem given during the ischemic period enhances systolic contractile function of postischemic stunned myocardium.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1869751     DOI: 10.1016/0735-1097(91)90814-p

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

Review 1.  Calcium antagonists in the post-myocardial infarction setting.

Authors:  B D Bertolet
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 2.  Cardioprotection and myocardial reperfusion: pitfalls to clinical application.

Authors:  Richard S Vander Heide; Charles Steenbergen
Journal:  Circ Res       Date:  2013-08-02       Impact factor: 17.367

3.  Limitation of infarct size with preconditioning and calcium antagonist (diltiazem): difference in 99mTc-PYP uptake in the myocardium.

Authors:  K Okuda; R Nohara; M Ogino; N Tamaki; J Konishi; M Fujita; S Sasayama
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

4.  Protective effect of urapidil on testicular torsion-detorsion injury in rats.

Authors:  Jakov Meštrović; Zenon Pogorelić; Irena Drmić-Hofman; Katarina Vilović; Davor Todorić; Marijana Popović
Journal:  Surg Today       Date:  2016-07-21       Impact factor: 2.549

5.  Urapidil alleviates ovarian torsion detorsion injury via regulating oxidative stress, apoptosis, autophagia, and inflammation.

Authors:  Mustafa Can Güler; Ayhan Tanyeli; Derya Güzel Erdoğan; Ersen Eraslan; Selim Çomaklı; Elif Polat; Songül Doğanay
Journal:  Iran J Basic Med Sci       Date:  2021-07       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.